Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

EARLY_PHASE1

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial

NCT02875262

Intracranial Aneurysm Subarachnoid Hemorrhage

UNKNOWN PHASE1/PHASE2

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

NCT04566991

Aneurysmal Subarachnoid Hemorrhage

RECRUITING PHASE2

A Phase Ib/II in Patients With Acute Ischemic Stroke

NCT02963376

Ischemic Stroke

COMPLETED PHASE1

Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage

NCT02687191

Intracerebral Hemorrhage

TERMINATED PHASE1

Delipid Extracorporeal Lipoprotein Filter From Plasma (DELP) for Acute Hemorrhagic Stroke

NCT05128513

Hemorrhagic Stroke

SUSPENDED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subarachnoid Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Desferrioxamine (DFO)

DFO (20mg/kg/hr) in normal saline IV for 4 hours for 5 consecutive days

Group Type ACTIVE_COMPARATOR

desferrioxamine (DFO)

Intervention Type DRUG

DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days

placebo

normal saline IV for 4 hours for 5 consecutive days

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

normal saline IV for 4 hours for 5 consecutive days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

desferrioxamine (DFO)

DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days

Intervention Type DRUG

placebo

normal saline IV for 4 hours for 5 consecutive days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

deferoxamine, desferal, DFO, deferoxamine mesylate normal saline NS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of spontaneous SAH
* impaired cerebral autoregulation on day 2-4 post SAH

Exclusion Criteria

* traumatic SAH
* other central neurological disorders such as tumors, known prior stroke, hemorrhage or vascular malformations
* pregnancy
* severe renal disease or anuria

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No